1994

Established Yantai Luye Pharmaceutical Co., Ltd. to engage in the manufacture and sale of pharmaceutical drugs and active ingredients.

1995

Commenced production of the natural active ingredient Sodium Aescinate and our main natural drug, Sodium Aescinate for Injection (Maitongna).

1997

Incorporated Luye Drugs Trading to distribute the products of other pharmaceutical manufacturers in the PRC.

1998

Established our Research and Development Centre to focus on R&D to develop new natural active ingredients and drugs with new formulations.

1999

Successfully launched Nuosen (Sodium Pantoprazole for Injection), a newly formulated prescription drug used for the treatment of gastroenterological ailments, throughout the PRC.Granted a “Post-doctorate Scientific Research Work-station” by the State Personnel Ministry.

2000

Obtained GMP certification for our production line and manufacturing process for tablets, capsules and granules.Our R&D Centre was recognized by the Shandong Science and Technology Committee as a “Shandong Natural Drug Engineering Research and Development Centre”.Obtained GMP certification for our lyophilized powder injection production line and manufacturing process.

2001

Nominated by the Ministry of Science and Technology as a production base to industralise the results of the National High Tech Research and Development Programme ("State 863 Programme").

2002

Launched Olai (Compound Sodium Aescinate Gel), manufactured from the natural ingredient Sodium Aescinate.Obtained patent for the composition with low toxicity for anti-inflammation and anti-exudation of Sodium Aescinate from US Patent and Trademark Office for 20 years.

2003

Obtained GMP certification for our production line and manufacturing process for gel and raw material, Sodium Aescinate.Launched Lutingnuo (Reduced Glutathione for Injection), principally used for the treatment of liver ailments.

2004

Listed on SGX main board

2006

Acquires all rights to Oncology Drug CMNa together with its market distribution networks

2007

Acquires Oncology specializing Nanjing Kanghai, Nanjing Sike pharmaceutical group

Acquires 43% interest in WBL Peking University Biotech Co. Ltd & its subsidiaries ("WPU"), a Beijing-based company with leading anti-cholesterol drug – Xuezhikang (血脂康®), reaffirming AsiaPharm's position as a leading pharmaceutical group in the PRC

Acquires 100% interest in Wearnes Biotech & Medicals (1998) Pte Ltd& its subsidiary ("WBM"), a Singapore pharmaceutical distributor for S$2.1 million; expanding the Group's distribution network in OTC drugs to South-east Asia and other countries.

AsiaPharm awards exclusive PRC distribution agreement for its proprietary neurology drug JinSiPing (金思平®) to international pharmaceutical conglomerate Sandoz, a Novartis company.